Statement of Deviation or Variation for half year ended on September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemant Surgical Industries has filed a routine regulatory disclosure confirming that there has been no deviation or variation in the use of funds raised through its IPO in May 2023. The company raised Rs. 2,848 lakhs via the IPO, with net fresh issue proceeds of Rs. 2,484 lakhs earmarked across four objects: Public Issue Expenses (Rs. 313.88 lakhs), Working Capital (Rs. 1,000 lakhs), Capital Expenditure for installation (Rs. 751.26 lakhs), and General Corporate Purpose (Rs. 418.86 lakhs). As of September 30, 2025, the full Rs. 2,484 lakhs has been utilized in line with the original allocation. The audit committee and auditors have raised no comments, and no monitoring agency was appointed for this issue.
This is a routine compliance filing with no negative signal — it reassures shareholders that IPO funds have been deployed exactly as promised in the prospectus, with no misuse or diversion. No material stock price impact is expected.